VYNE Therapeutics Inc. financial data

Symbol
VYNE on Nasdaq
Industry
Pharmaceutical Preparations
Location
685 Route 202/206 N., Suite 301, Bridgewater, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
Menlo Therapeutics Inc. (to 9/2/2020), Menlo Therapeutics, Inc. (to 1/31/2018), Tigercat Pharma, Inc. (to 1/7/2013)
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 676 % +11.2%
Debt-to-equity 17.4 % -24.8%
Return On Equity -58.2 % +26.4%
Return On Assets -49.6 % +22.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15.2M shares +4.69%
Common Stock, Shares, Outstanding 14.8M shares +5.19%
Entity Public Float 28.2M USD +115%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 42.6M shares +315%
Weighted Average Number of Shares Outstanding, Diluted 42.6M shares +315%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 501K USD +18.2%
Research and Development Expense 30.9M USD +89.8%
General and Administrative Expense 13.2M USD -1.37%
Costs and Expenses 44.1M USD +48.7%
Operating Income (Loss) -43.6M USD -49.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -39.8M USD -42.8%
Income Tax Expense (Benefit) 4K USD
Net Income (Loss) Attributable to Parent -39.8M USD -40%
Earnings Per Share, Basic -0.93 USD/shares +66.5%
Earnings Per Share, Diluted -0.93 USD/shares +66.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.9M USD -34.9%
Marketable Securities, Current 41.6M USD -33.6%
Accounts Receivable, after Allowance for Credit Loss, Current 250K USD -46.9%
Assets, Current 64.4M USD -32.9%
Property, Plant and Equipment, Net 113K USD
Operating Lease, Right-of-Use Asset 93K USD -55.1%
Assets 66.9M USD -31.5%
Employee-related Liabilities, Current 1.43M USD -13.2%
Accrued Liabilities, Current 9.27M USD +125%
Liabilities, Current 14.8M USD +96.6%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 14.8M USD +65.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 20K USD -23.1%
Retained Earnings (Accumulated Deficit) -731M USD -5.76%
Stockholders' Equity Attributable to Parent 52.1M USD -41.3%
Liabilities and Equity 66.9M USD -31.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.98M USD -45.7%
Net Cash Provided by (Used in) Financing Activities -217K USD -114%
Net Cash Provided by (Used in) Investing Activities -3.57M USD -171%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 14.8M shares +5.19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.6M USD -1563%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.9M USD -35%
Deferred Tax Assets, Valuation Allowance 101M USD +12.1%
Deferred Tax Assets, Gross 101M USD +12.1%
Operating Lease, Liability 99K USD -53.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -39.8M USD -40.2%
Lessee, Operating Lease, Liability, to be Paid 101K USD -55.7%
Property, Plant and Equipment, Gross 117K USD
Operating Lease, Liability, Current 99K USD -13.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 102K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 101K USD -19.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2K USD -85.7%
Deferred Tax Assets, Operating Loss Carryforwards 75.9M USD +4.71%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 2.57M USD +4.39%
Additional Paid in Capital 783M USD +0.41%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 3.3M USD -0.06%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%